33.53
price down icon0.47%   -0.16
after-market Handel nachbörslich: 33.53
loading
Schlusskurs vom Vortag:
$33.69
Offen:
$34.41
24-Stunden-Volumen:
1.08M
Relative Volume:
0.69
Marktkapitalisierung:
$5.45B
Einnahmen:
$1.51B
Nettoeinkommen (Verlust:
$333.35M
KGV:
17.19
EPS:
1.95
Netto-Cashflow:
$315.22M
1W Leistung:
-1.15%
1M Leistung:
-1.50%
6M Leistung:
+21.79%
1J Leistung:
+23.05%
1-Tages-Spanne:
Value
$33.50
$34.45
1-Wochen-Bereich:
Value
$33.22
$35.41
52-Wochen-Spanne:
Value
$22.90
$36.45

Alkermes Plc Stock (ALKS) Company Profile

Name
Firmenname
Alkermes Plc
Name
Telefon
00-353-1-772-8000
Name
Adresse
CONNAUGHT HOUSE, DUBLIN 4
Name
Mitarbeiter
1,800
Name
Twitter
@alkermes
Name
Nächster Verdiensttermin
2024-10-24
Name
Neueste SEC-Einreichungen
Name
ALKS's Discussions on Twitter

Vergleichen Sie ALKS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
ALKS
Alkermes Plc
33.53 5.45B 1.51B 333.35M 315.22M 1.95
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
165.02 73.07B 9.26B 2.49B 2.30B 5.47
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.14 47.43B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.12 45.72B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
15.49 17.75B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
ITCI
Intra Cellular Therapies Inc
131.75 14.03B 612.78M -86.37M -62.91M -0.87

Alkermes Plc Stock (ALKS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-13 Eingeleitet RBC Capital Mkts Sector Perform
2025-03-04 Hochstufung UBS Sell → Neutral
2025-02-11 Eingeleitet Deutsche Bank Buy
2024-11-05 Hochstufung Stifel Hold → Buy
2024-06-17 Eingeleitet TD Cowen Buy
2024-03-19 Eingeleitet Robert W. Baird Outperform
2024-02-20 Herabstufung UBS Neutral → Sell
2023-11-20 Fortgesetzt JP Morgan Neutral
2023-10-24 Hochstufung Evercore ISI In-line → Outperform
2023-10-17 Eingeleitet UBS Neutral
2022-11-03 Hochstufung Piper Sandler Neutral → Overweight
2022-10-14 Hochstufung BofA Securities Underperform → Neutral
2022-08-16 Eingeleitet Piper Sandler Neutral
2022-04-22 Fortgesetzt Goldman Buy
2022-04-20 Eingeleitet Goldman Buy
2022-01-27 Hochstufung Cantor Fitzgerald Hold → Overweight
2021-12-01 Eingeleitet Citigroup Neutral
2021-10-07 Hochstufung Jefferies Hold → Buy
2021-09-02 Herabstufung BofA Securities Neutral → Underperform
2020-10-15 Hochstufung Mizuho Neutral → Buy
2020-07-30 Herabstufung Goldman Neutral → Sell
2020-02-14 Herabstufung BofA/Merrill Buy → Neutral
2020-02-14 Bestätigt H.C. Wainwright Neutral
2020-02-14 Herabstufung JP Morgan Overweight → Neutral
2020-02-06 Eingeleitet Mizuho Neutral
2020-01-31 Hochstufung Wolfe Research Underperform → Peer Perform
2019-09-05 Hochstufung Morgan Stanley Underweight → Equal-Weight
2019-07-15 Hochstufung Goldman Sell → Neutral
2019-05-31 Eingeleitet H.C. Wainwright Neutral
2019-05-01 Herabstufung Citigroup Buy → Neutral
2018-12-19 Herabstufung Goldman Neutral → Sell
2018-12-14 Eingeleitet Wolfe Research Underperform
2018-12-13 Herabstufung Credit Suisse Outperform → Underperform
2018-11-05 Eingeleitet Piper Jaffray Neutral
2018-08-07 Eingeleitet Stifel Hold
2018-06-21 Herabstufung Morgan Stanley Equal-Weight → Underweight
2018-06-06 Eingeleitet B. Riley FBR, Inc. Buy
2018-05-16 Hochstufung Citigroup Neutral → Buy
2018-05-11 Eingeleitet BofA/Merrill Buy
Alle ansehen

Alkermes Plc Aktie (ALKS) Neueste Nachrichten

pulisher
08:14 AM

Deutsche Bank Adjusts Alkermes Public Price Target to $52 From $40, Maintains Buy Rating - Marketscreener.com

08:14 AM
pulisher
08:00 AM

What 5 Analyst Ratings Have To Say About Alkermes - Benzinga

08:00 AM
pulisher
07:00 AM

New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder - PR Newswire

07:00 AM
pulisher
Mar 26, 2025

Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition? - MSN

Mar 26, 2025
pulisher
Mar 25, 2025

Mural Oncology stock plunges on trial halt (MURA:NASDAQ) - Seeking Alpha

Mar 25, 2025
pulisher
Mar 25, 2025

Liposomal Drug Delivery Market Detailed In New Research Report - openPR

Mar 25, 2025
pulisher
Mar 21, 2025

First Week of November 21st Options Trading For Alkermes (ALKS) - Nasdaq

Mar 21, 2025
pulisher
Mar 20, 2025

Controlled Release Drug Delivery Market to Witness Massive - openPR

Mar 20, 2025
pulisher
Mar 19, 2025

Alkermes price target raised to $35 from $34 at BofA - MSN

Mar 19, 2025
pulisher
Mar 18, 2025

Where are the Opportunities in (ALKS) - Stock Traders Daily

Mar 18, 2025
pulisher
Mar 15, 2025

Insider Sale at Alkermes PLC: EVP R&D, Chief Medical Officer Cra - GuruFocus.com

Mar 15, 2025
pulisher
Mar 14, 2025

Why Is Alkermes (ALKS) Down 6.6% Since Last Earnings Report? - Yahoo Finance

Mar 14, 2025
pulisher
Mar 14, 2025

Is Alkermes plc (ALKS) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey

Mar 14, 2025
pulisher
Mar 14, 2025

Alkermes PLC Reports Q4 Revenue of $430 Million, Beating Estimat - GuruFocus.com

Mar 14, 2025
pulisher
Mar 14, 2025

Alkermes' (NASDAQ:ALKS) investors will be pleased with their splendid 140% return over the last five years - Yahoo Finance

Mar 14, 2025
pulisher
Mar 14, 2025

Alkermes (NASDAQ:ALKS) shareholders have earned a 19% CAGR over the last five years - Simply Wall St

Mar 14, 2025
pulisher
Mar 13, 2025

Alkermes Facing Near-Term Headwinds Across Existing Franchises, Royalties, RBC Says - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

RBC Capital Initiates Coverage of Alkermes (ALKS) with Sector Perform Recommendation - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

S&P 500 Futures Drop in Premarket Trading; Alkermes, Intel Lead - Barron's

Mar 13, 2025
pulisher
Mar 13, 2025

Alkermes initiated with a Sector Perform at RBC Capital - TipRanks

Mar 13, 2025
pulisher
Mar 13, 2025

Charles Schwab Investment Management Inc. Sells 38,088 Shares of Alkermes plc (NASDAQ:ALKS) - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Alkermes at Leerink’s Global Healthcare Conference: Strategic Pipeline Insights - Investing.com India

Mar 12, 2025
pulisher
Mar 12, 2025

Alkermes at Leerink’s Global Healthcare Conference: Strategic Pipeline Insights By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 12, 2025

Alkermes to Participate in Upcoming Investor Conferences - GuruFocus.com

Mar 12, 2025
pulisher
Mar 11, 2025

Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones - The Manila Times

Mar 11, 2025
pulisher
Mar 09, 2025

Alkermes Plc to Host Earnings Call - ACCESS Newswire

Mar 09, 2025
pulisher
Mar 09, 2025

Alkermes plc (NASDAQ:ALKS) Shares Bought by Smartleaf Asset Management LLC - Defense World

Mar 09, 2025
pulisher
Mar 09, 2025

Proficio Capital Partners LLC Buys New Stake in Alkermes plc (NASDAQ:ALKS) - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

(ALKS) Technical Pivots with Risk Controls - Stock Traders Daily

Mar 08, 2025
pulisher
Mar 08, 2025

What is Zacks Research’s Estimate for Alkermes Q1 Earnings? - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

Zacks Research Predicts Alkermes FY2027 Earnings - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

UBS Group Upgrades Alkermes (NASDAQ:ALKS) to Neutral - MarketBeat

Mar 07, 2025
pulisher
Mar 06, 2025

Y Intercept Hong Kong Ltd Invests $413,000 in Alkermes plc (NASDAQ:ALKS) - MarketBeat

Mar 06, 2025
pulisher
Mar 05, 2025

UBS Upgrades Alkermes (ALKS) - Nasdaq

Mar 05, 2025
pulisher
Mar 05, 2025

Bank of New York Mellon Corp Has $61.45 Million Stock Holdings in Alkermes plc (NASDAQ:ALKS) - Defense World

Mar 05, 2025
pulisher
Mar 05, 2025

Alkermes (NASDAQ:ALKS) Upgraded to Neutral at UBS Group - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

UBS Upgrades Alkermes to Neutral From Sell, $38 Price Target -March 04, 2025 at 08:27 am EST - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Alkermes upgraded to Neutral from Sell at UBS - TipRanks

Mar 04, 2025
pulisher
Mar 01, 2025

Alkermes plc (ALKS): Among the Best Psychedelic Stocks to Buy in 2025 - Insider Monkey

Mar 01, 2025
pulisher
Mar 01, 2025

New York State Common Retirement Fund Increases Holdings in Alkermes plc (NASDAQ:ALKS) - Defense World

Mar 01, 2025
pulisher
Feb 28, 2025

Ieq Capital LLC Acquires New Stake in Alkermes plc (NASDAQ:ALKS) - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Alkermes VP Samuel Parisi sells $65,892 in shares - Investing.com India

Feb 28, 2025
pulisher
Feb 28, 2025

Alkermes VP Samuel Parisi sells $65,892 in shares By Investing.com - Investing.com UK

Feb 28, 2025
pulisher
Feb 28, 2025

Illinois Municipal Retirement Fund Sells 11,878 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat

Feb 28, 2025
pulisher
Feb 27, 2025

Alkermes plc (NASDAQ:ALKS) is HealthInvest Partners AB's 10th Largest Position - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

C WorldWide Group Holding A S Purchases Shares of 250,000 Alkermes plc (NASDAQ:ALKS) - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

Todd Asset Management LLC Sells 30,957 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

Sanctuary Advisors LLC Acquires 1,917 Shares of Alkermes plc (NASDAQ:ALKS) - Defense World

Feb 27, 2025
pulisher
Feb 26, 2025

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes plc To Contact The Firm - ACCESS Newswire

Feb 26, 2025
pulisher
Feb 26, 2025

Blue Trust Inc. Purchases 1,629 Shares of Alkermes plc (NASDAQ:ALKS) - Defense World

Feb 26, 2025
pulisher
Feb 25, 2025

Alkermes VP of finance Samuel Joseph Parisi sells shares worth $131,978 By Investing.com - Investing.com South Africa

Feb 25, 2025

Finanzdaten der Alkermes Plc-Aktie (ALKS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$10.81
price up icon 2.46%
$97.04
price down icon 1.41%
$8.84
price down icon 1.34%
$114.00
price down icon 0.39%
$131.75
price up icon 0.05%
Kapitalisierung:     |  Volumen (24h):